Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis

Theranostics

Volumn 4, Issue 2, 2014, Pages 175-200

  Yin, Rui Xing ^a   Yang, De Zhai ^a   Wu, Jin Zhen ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Coronary artery disease; Nanoparticle; Restenosis; Stenosis; Stents

Indexed keywords

CORONARY ARTERY DISEASE; NANOPARTICLE.; RESTENOSIS; STENOSIS; STENTS;

BIOMEDICAL RESEARCH; CARDIOVASCULAR AGENTS; CHEMOPREVENTION; CORONARY RESTENOSIS; GENETIC THERAPY; HUMANS; NANOPARTICLES; STENTS;

EID: 84893621678     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7210     Document Type: Review

References (203)

1. Deaton C, Froelicher ES, Wu LH, Ho C, et al. The global burden of cardiovascular disease. J Cardiovasc Nurs. 2011;26(4 Suppl):S5-S14.
2. [Internet] WHO. World Health Statistics 2008. http://www.who.int/whosis/whostat/2008/en/index.html
3. Kavanagh CA, Rochev YA, Gallagher WM, et al. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. Pharmacol Ther. 2004;102:1-15.
4. Hamon M, Lecluse E, Monassier JP, et al. Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Drugs Aging. 1998; 13:291-301.
5. Burta HM, Hunter WL. Drug-eluting stents: a multidisciplinary success story. Adv Drug Deliv Rev. 2006;58:350-7.
6. Panyam J, Labbhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329-47.
7. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 1999;10:499-506.
8. Tepe G, Wendel HP, Khorchidi S, et al. Thrombogenicity of various endovascular stent types: an in vitro evaluation. J Vasc Interv Radiol. 2002;13:1029-35.
9. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166-70.
10. van der Hoeven BL, Pires NM, Warda HM, et al. Drug-eluting stents: results, promises and problems. Int J Cardiol. 2005;99:9-17.
11. Tan A, Farhatnia Y, de Mel A, et al. Inception to actualization: next generation coronary stent coatings incorporating nanotechnology. J Biotechnol. 2013;164:151-70.
12. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-96.
13. Brito LA, Chandrasekhar S, Little SR, et al. In vitro and in vivo studies of local arterial gene delivery and transfection using lipopolyplexes-embedded stents. J Biomed Mater Res A. 2010;93:325-36.
14. IndolfiC, Coppola C, Torella D, et al. Gene therapy for restenosis after balloon angioplasty and stenting. Cardiol Rev. 1999;7:324-31.
15. IndolfiC, Torella D, Coppola C, et al. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am J Physiol Heart Circ Physiol. 2002;283:H760-H767.
16. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-5.
17. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43.
18. Dangas G, Fuster V. Management of restenosis after coronary intervention. Am Heart J. 1996 ;132(2 Pt 1):428-36.
19. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697-703.
20. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872-8.
21. Scott NA. Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev. 2006;58:358-76.
22. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247-54.
23. Nakatani M, Takeyama Y, Shibata M, et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol. 2003;12:40-8.
24. Miano JM, Vlasic N, Tota RR, et al. Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol. 1993;142:715-24.
25. Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-80.
26. Farb A, Kolodgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110:940-7.
27. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769-76.
28. Riessen R, Wight TN, Pastore C, et al. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon- injured rat carotid arteries. Circulation. 1996;93:1141-7.
29. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257-73.
30. Grube E, Gerckens U, Müller R, et al. Drug eluting stents: initial experiences. Z Kardiol. 2002;91(Suppl 3):44-8.
31. Voisard R, Dartsch PC, Seitzer U, et al. The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries. Coron Artery Dis. 1993;4:935-42.
32. Voisard R, Seitzer U, Baur R, et al. A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Int J Cardiol. 1995;51:15-28.
33. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-7.
34. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869-76.
35. Charles R, Sandirasegarane L, Yun J, et al. Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res. 2000;87:282-8.
36. Tanabe Y, Ito E, Nakagawa I, et al. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol. 2001;78:285-91.
37. Ahrens I, Peter K, Bode C. Use of GPIIb/IIIa inhibitors in cardiovascular medicine. Expert Rev Cardiovasc Ther. 2003;1:233-42.
38. Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate- containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 2002;106:599-605.
39. Danenberg HD, Fishbein I, Epstein H, et al. Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol. 2003;42:671-9.
40. Banai S, Wolf Y, Golomb G, et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 1998;97:1960-9.
41. Banai S, Chorny M, Gertz SD, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials. 2005;26:451-61.
42. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine- coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv. 2002;57:266-71.
43. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-35.
44. Ishiwata S, Verheye S, Robinson KA, et al. Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation. J Am Coll Cardiol. 2000;35:1331-7.
45. Peters S, Götting B, Trümmel M, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol. 2001;13:93-7.
46. Walter DH, Schächinger V, Elsner M, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol. 2000;85:962-8.
47. Dangas G, Iakovou I. The end of systemic anticoagulation therapy for restenosis prevention. J Invasive Cardiol. 2001;13:729-31.
48. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-5.
49. Gingras AC, Raught B, Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol. 2004;279:169-97.
50. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-11.
51. Aoki J, Abizaid AC, Serruys PW, et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol. 2005;46:1670-6.
52. Serruys PW, Garg S, Abizaid A, et al. A randomised comparison of novolimus- eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention. 2010;6:195-205.
53. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
54. Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005;1:58-65.
55. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-42.
56. Haraguchi G, Pruitt S, Brodeur A, et al. Increased expression of eNOS by Endeavor zotarolimus-eluting stents compared to other DES in porcine coronary artery implants. Am J Cardiol. 2006;98(Suppl):32-3.
57. Ostojic M, Sagic D, Jung R, et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv. 2008;72:901-8.
58. Ostojic MC, Perisic Z, Sagic D, et al. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study. Eur J Clin Pharmacol. 2011;67:389-98.
59. Vetrovec GW, Rizik D, Williard C, et al. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv. 2006;67:32-7.
60. Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol. 2008;51:2123-9.
61. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005;112:2002-11.
62. Morice MC, Bestehorn HP, Carrié D, et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention. 2006;2:45-52.
63. Zollinger M, Waldmeier F, Hartmann S, et al. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006;34:765-74.
64. Ormiston JA, Webster MW, Schwartz RS, et al. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results. JACC Cardiovasc Interv. 2009;2:1017-24.
65. Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20:3806-13.
66. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948-54.
67. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double- trial on a slow-release paclitaxel- eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
68. Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation. 2004;109:627-33.
69. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-7.
70. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172-9.
71. Weissman NJ, Ellis SG, Grube E, et al. Effect of the polymer-based, paclitaxel- eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J. 2007;28:1574-82.
72. Serruys PW, Ormiston JA, Sianos G, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol. 2004;44:1363-7.
73. Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays. 1996;18:371-8.
74. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv. 2003;60:172-9.
75. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-7.
76. van der Harst P, Groenewegen HC, Roks AJ, et al. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Coron Artery Dis. 2008;19:47-53.
77. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122:2301-12.
78. LincoffAM, Furst JG, Ellis SG, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 1997; 29:808-16.
79. Rajtar A, Kaluza GL, Yang Q, et al. Hydroxyapatite-coated cardiovascular stents. EuroIntervention. 2006;2:113-5.
80. Remuzzi A, Mantero S, Colombo M, et al. Vascular smooth muscle cells on hyaluronic acid: culture and mechanical characterization of an engineered vascular construct. Tissue Eng. 2004;10:699-710.
81. Travis JA, Hughes MG, Wong JM, et al. Hyaluronan enhances contraction of collagen by smooth muscle cells and adventitial fibroblasts: Role of CD44 and implications for constrictive remodeling. Circ Res. 2001;88:77-83.
82. Heublein B, Evagorou EG, Rohde R, et al. Polymerized degradable hyaluronan-- a platform for stent coating with inherent inhibitory effects on neointimal formation in a porcine coronary model. Int J Artif Organs. 2002;25:1166-73.
83. Jensen DK, Jensen LB, Koocheki S, et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release. 2012;157:141-8.
84. Steinbach JM, Weller CE, Booth CJ, et al. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release. 2012;162:102-10.
85. Chorny M, Fishbein I, Yellen BB, et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci USA. 2010;107:8346-51.
86. Yuan X, Shah BA, Kotadia NK, et al. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res. 2010;27:1285-95.
87. Zhu D, Jin X, Leng X, et al. Local gene delivery via endovascular stents coated with dodecylated chitosan-plasmid DNAnanoparticles. Int J Nanomedicine. 2010;5:1095-102.
88. KrucoffMW, Kereiakes DJ, Petersen JL, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. Am Coll Cardiol. 2008;51:1543-52.
89. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-73.
90. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30:2441-9.
91. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399-404.
92. RadeleffB, Thierjung H, StampflU, et al. Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model. Cardiovasc Intervent Radiol. 2008;31:971-80.
93. Tamburino C, La Manna A, Di Salvo ME, et al. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. JACC Cardiovasc Interv. 2009;2:197-204.
94. La Manna A, Capodanno D, Cera M, et al. Optical coherence tomographic results at six-month follow-up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial). Am J Cardiol. 2009;103:1551-5.
95. Khan W, Farah S, Domb AJ. Drug eluting stents: developments and current status. J Control Release. 2012;161:703-12.
96. Rogers CD. Optimal stent design for drug delivery. Rev Cardiovasc Med. 2004;5(Suppl 2):S9-S15.
97. Abizaid A, Costa JR Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv. 2010;3:384-93.
98. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57:1700-8.
99. Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol. 2010;56:264-71.
100. Capodanno D, Dipasqua F, Tamburino C. Novel drug-eluting stents in the treatment of de novo coronary lesions. Vasc Health Risk Manag. 2011;7:103-18.
101. Ormiston JA, Lefèvre T, Grube E, et al. First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent. EuroIntervention. 2010;6:46-53.
102. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56(10 Suppl):S43-S78.
103. Costa RA, Abizaid A, Abizaid AS, et al. Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial. EuroIntervention. 2012;7:1301-9.
104. Verheye S, Ramcharitar S, Grube E, et al. Six-month clinical and angiographic results of the STENTYS self-apposing stent in bifurcation lesions. EuroIntervention. 2011;7:580-7.
105. Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 2003;108:2798-804.
106. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation. 2002;106:1195-8.
107. Margolis J, McDonald J, Heuser R, et al. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin Cardiol. 2007;30:165-70.
108. Joner M, Morimoto K, Kasukawa H, et al. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler Thromb Vasc Biol. 2008;28:1960-6.
109. Chan JM, Rhee JW, Drum CL, et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A. 2011;108:19347-52.
110. Lanza GM, Yu X, Winter PM, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation. 2002;106:2842-7.
111. Ceylan H, Tekinay AB, Guler MO. Selective adhesion and growth of vascular endothelial cells on bioactive peptide nanofiber functionalized stainless steel surface. Biomaterials. 2011;32:8797-805.
112. Polyak B, Fishbein I, Chorny M, et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A. 2008;105:698-703.
113. Masuda S, Nakano K, Funakoshi K, et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J Atheroscler Thromb. 2011;18:1043-53.
114. Bhargava B, Reddy NK, Karthikeyan G, et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv. 2006;67:698-702.
115. Tsukie N, Nakano K, Matoba T, et al. Pitavastatin-incorporated nanoparticle- eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J Atheroscler Thromb. 2013;20:32-45.
116. Luderer F, Löbler M, Rohm HW, et al. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stentrestenosis in coronary stent application. J Biomater Appl. 2011;25:851-75.
117. Räthel T, Mannell H, Pircher J, et al. Magnetic stents retain nanoparticle-bound antirestenotic drugs transported by lipid microbubbles. Pharm Res. 2012;29:1295-307.
118. Acharya G, Lee CH, Lee Y. Optimization of cardiovascular stent against restenosis: factorial design-based statistical analysis of polymer coating conditions. PLoS One. 2012;7:e43100.
119. Sharif F, Hynes SO, Cooney R, et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther. 2008;16:1674-80.
120. Muhs A, Heublein B, Schletter J, et al. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum Gene Ther. 2003;14:375-83.
121. Wang K, Kessler PD, Zhou Z, et al. Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol Ther. 2003;7(5 Pt 1):597-603.
122. Kim TG, Lee Y, Park TG. Controlled gene-eluting metal stent fabricated by bio-inspired surface modification with hyaluronic acid and deposition of DNA/PEI polyplexes. Int J Pharm. 2010;384:181-8.
123. Fishbein I, Alferiev I, Bakay M, et al. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation. 2008;117:2096-103.
124. Walter DH, Cejna M, Diaz-Sandoval L, et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation. 2004;110:36-45.
125. Fishbein I, Alferiev IS, Nyanguile O, et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci U S A. 2006;103:159-64.
126. Sharif F, Daly K, Crowley J, et al. Current status of catheter- and stent-based gene therapy. Cardiovasc Res. 2004;64:208-16.
127. Jin X, Mei L, Song C, et al. Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy. J Gene Med. 2008;10:421-9.
128. Bengali Z, Rea JC, Shea LD. Gene expression and internalization following vector adsorption to immobilized proteins: dependence on protein identity and density. J Gene Med. 2007;9:668-78.
129. Rutanen J, Markkanen J, Ylä-Herttuala S. Gene therapy for restenosis: current status. Drugs. 2002;62:1575-85.
130. Guzman RJ, Hirschowitz EA, Brody SL, et al. In vivo suppression of injury- induced vascular smooth muscle cell accumulation using adenovirus- mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA. 1994;91:10732-6.
131. Ogata H, Mishio M, Luo XX, et al. Significance of elevated cytochrome aa3 in a state of endotoxemia in dogs. Resuscitation. 1996;33:63-8.
132. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-4.
133. Simari RD, San H, Rekhter M, et al. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest. 1996;98:225-35.
134. Harrell RL, Rajanayagam S, Doanes AM, et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 1997;96:621-7.
135. Mano T, Luo Z, Suhara T, et al. Expression of wild-type and noncleavable fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions. Hum Gene Ther. 2000;11:1625-35.
136. Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994;94:978-84.
137. Chen D, Krasinski K, Sylvester A, et al. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997;99:2334-41.
138. Yonemitsu Y, Kaneda Y, Tanaka S, et al. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res. 1998;82:147-56.
139. Scheinman M, Ascher E, Kallakuri S, et al. P53 gene transfer to the injured rat carotid artery promotes apoptosis. Surgery. 1999;126:863-8.
140. Tanner FC, Boehm M, Akyürek LM, et al. Differential effects of the cyclin- dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000;101:2022-5.
141. Tsui LV, Camrud A, Mondesire J, et al. p27-p16 fusion gene inhibits angioplasty- induced neointimal hyperplasia and coronary artery occlusion. Circ Res. 2001;89:323-8.
142. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-22.
143. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 1995;92:5855-9.
144. Kawauchi M, Suzuki J, Morishita R, et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res. 2000;87:1063-8.
145. Wills KN, Mano T, Avanzini JB, et al. Tissue-specific expression of an anti- proliferative hybrid transgene from the human smooth muscle alpha-actin promoter suppresses smooth muscle cell proliferation and neointima formation. Gene Ther. 2001;8:1847-54.
146. Sinnaeve P, Chiche JD, Gillijns H, et al. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation. 2002;105:2911-6.
147. Frimerman A, Welch PJ, Jin X, et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation. 1999;99:697-703.
148. Maillard L, Van Belle E, Smith RC, et al. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res. 1997;35:536-46.
149. Stephan D, San H, Yang ZY, et al. Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon. Mol Med. 1997;3:593-9.
150. Ueno H, Yamamoto H, Ito S, et al. Adenovirus-mediated transfer of a dominant- negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol. 1997;17:898-904.
151. Mano T, Luo Z, Malendowicz SL, et al. Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery. Circ Res. 1999;84:647-54.
152. Maillard L, Van Belle E, Tio FO, et al. Effect of percutaneous adeno- virus- mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. Gene Ther. 2000;7:1353-61.
153. Lowe HC, Fahmy RG, Kavurma MM, et al. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res. 2001;89:670-7.
154. Tulis DA, Durante W, Liu X, et al. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 2001;104:2710-5.
155. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation. 2004;109:1769-75.
156. Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-91.
157. Furman C, Luo Z, Walsh K, et al. Systemic tissue inhibitor of metalloproteinase- 1 gene delivery reduces neointimal hyperplasia in balloon- injured rat carotid artery. FEBS Lett. 2002;531:122-6.
158. Turunen MP, Puhakka HL, Koponen JK, et al. Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther. 2002;6:306-12.
159. Turunen P, Puhakka HL, Heikura T, et al. Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase- 1: Combination gene therapy in the treatment of vein graft stenosis in rabbits. Hum Gene Ther. 2006;17:405-14.
160. Puhakka HL, Turunen P, Gruchala M, et al. Effects of vaccinia virus anti- inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. In Vivo. 2005;19:515-21.
161. Puhakka HL, Turunen P, Rutanen J, et al. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res. 2005;42:361-7.
162. Asahara T, Chen D, Tsurumi Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation. 1996;94:3291-302.
163. Hiltunen MO, Laitinen M, Turunen MP, et al. Intravascular adenovirus- mediated VEGF-C gene transfer reduces neointima formation in balloon- denuded rabbit aorta. Circulation. 2000;102:2262-8.
164. Rade JJ, Schulick AH, Virmani R, et al. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med. 1996;2:293-8.
165. Zoldhelyi P, Chen ZQ, Shelat HS, et al. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A. 2001;98:4078-83.
166. Yin X, Yutani C, Ikeda Y, et al. Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc Res. 2002;56:454-63.
167. Yin X, Fu Y, Yutani C, et al. HVJ-AVE liposome-mediated tissue factor pathway inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries. Int J Cardiol. 2009;135:245-8.
168. Wu KK. Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Agents Actions Suppl. 1997;48:107-23.
169. Todaka T, Yokoyama C, Yanamoto H, et al. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats editorial Comment. Stroke. 1999;30:419-26.
170. Shyue SK, Tsai MJ, Liou JY, et al. Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer. Circulation. 2001;103:2090-5.
171. Numaguchi Y, Okumura K, Harada M, et al. Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries. Cardiovasc Res. 2004;61:177-85.
172. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 1995;92:1137-41.
173. Chen L, Daum G, Forough R, et al. Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ Res. 1998;82:862-70.
174. Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998;97:1274-81.
175. Shears LL 2nd, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg. 1998;187:295-306.
176. Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 1998;98:919-26.
177. Klugherz BD, Jones PL, Cui X, et al. Gene delivery from a DNA controlled- release stent in porcine coronary arteries. Nat Biotechnol. 2000;18:1181-4.
178. Sharif F, Hynes SO, McCullagh KJ, et al. Gene-eluting stents: non-viral, liposome- based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model. Gene Ther. 2012;19:321-8.
179. Egashira K, Nakano K, Ohtani K, et al. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol. 2007;27:2563-8.
180. Jin X, Mei L, Song C, et al. Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy. J Gene Med. 2008;10:421-9.
181. Perlstein I, Connolly JM, Cui X, et al. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther. 2003;10:1420-8.
182. Wang Y, Yu M, Zhang L, et al. Immobilization of gene vectors on bisphosphonate- mediated gene-eluting metal stents using antibody for localized gene delivery. J Control Release. 2011;152(Suppl 1):e173-e174.
183. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8.
184. Morishita R, Gibbons GH, Ellison KE, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-64.
185. Cohen-Sacks H, Najajreh Y, Tchaikovski V, et al. Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther. 2002;9:1607-16.
186. Johnson TW, Wu YX, Herdeg C, et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler Thromb Vasc Biol. 2005;25:754-9.
187. Klugherz BD, Song C, DeFelice S, et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther. 2002;13:443-54.
188. Chorny M, Fishbein I, Alferiev IS, et al. Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression. Mol Ther. 2006;14:382-91.
189. Brito LA, Chandrasekhar S, Little SR, et al. Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. Biomed Eng Online. 2010;9:56.
190. Takemoto Y, Kawata H, Soeda T, et al. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. Arterioscler Thromb Vasc Biol. 2009;29:857-62.
191. Godin B, Sakamoto JH, Serda RE, et al. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci. 2010;31:199-205.
192. Martinez AW, Chaikof EL. Microfabrication and nanotechnology in stent design. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:256-68.
193. Kipshidze NN, Iversen P, Kim HS, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv. 2004;61:518-27.
194. Kipshidze N, Iversen P, Overlie P, et al. First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovasc Revasc Med. 2007;8:230-5.
195. Jere D, Arote R, Jiang HL, et al. Biodegradable nano-polymeric system for efficient Akt1 siRNA delivery. J Nanosci Nanotechnol. 2010;10:3366-9.
196. Jiang HL, Hong SH, Kim YK, et al. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. Int J Pharm. 2011;420:256-65.
197. Che HL, Bae IH, Lim KS, et al. Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model. Biomaterials. Biomaterials. 2012;33:8548-56.
198. Kalra M, Jost CJ, Severson SR, et al. Adventitial versus intimal liposome- mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene. J Vasc Surg. 2000;32:1190-200.
199. Lahtinen M, Blomberg P, Baliulis G, et al. In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts. Eur J Cardiothorac Surg. 2007;31:383-90.
200. Swanson N, Hogrefe K, Javed Q, et al. Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia. J Invasive Cardiol. 2003;15:688-92.
201. Paul A, Shao W, Shum-Tim D, et al. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNA(Ang1+Vegf) nanoparticles. Biomaterials. 2012;33:7655-64.
202. Yang J, Zeng Y, Zhang C, et al. The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. Biomaterials. 2013;34:1635-43.
203. Lemos PA, Farooq V, Takimura CK, et al. Emerging technologies: polymer- free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9:148-56.